ANA Spotlights - Migraine Prevention: Can We Do More? Exploring the implications of Migraine and VYEPTI (eptinezumab-jjmr)

Please see Important Safety Information below.




Learn More

Featured Video

Listen to a recording from the Satellite Symposium at ANA-AHS SIG Session presented on November 1, 2021.  In this video Drs. Dawn Buse and Andrew Charles discuss and review selected data related to the burden and stigma of living with a chronic disease.  They will also review the efficacy and safety of VYEPTI. Hear a real patient share her personal experience about the burden of a chronic condition and treatment with VYEPTI.


Dawn C. Buse, PhD
Clinical Professor, Department of Neurology
Albert Einstein College of Medicine of Yeshiva University
Assistant Professor, Clinical Health Psychology Doctoral Program
Ferkauf Graduate School of Psychology of Yeshiva University

Andrew C. Charles, MD
Professor of Neurology
Director, UCLA Goldberg Migraine Program
Meyer and Renee Luskin Chair in Migraine and Headache Studies
David Geffen School of Medicine at UCLA

Disclaimer: The following video is a paid advertisement and viewers are not to consider the contents as an endorsement of products or services by the ANA. The materials, information or opinions provided during the videos are solely those of the individuals and companies involved and do not necessarily represent those of the ANA.

ANA Spotlights:



VYEPTI is indicated for the preventive treatment of migraine in adults.



VYEPTI is contraindicated in patients with serious hypersensitivity to eptinezumab-jjmr or to any of the excipients. Reactions have included anaphylaxis and angioedema.


Hypersensitivity reactions: Hypersensitivity reactions, including angioedema, urticaria, facial flushing, and rash, have occurred with VYEPTI in clinical trials. Most hypersensitivity reactions occurred during infusion and were not serious, but often led to discontinuation or required treatment. Serious hypersensitivity reactions may occur. Cases of anaphylaxis have occurred in the postmarketing setting. If a hypersensitivity reaction occurs, consider discontinuing VYEPTI, and institute appropriate therapy.


The most common adverse reactions (≥2% and at least 2% or greater than placebo) in the clinical trials for the preventive treatment of migraine were nasopharyngitis and hypersensitivity.

For more information, please see the Prescribing Information and Patient Information; or go to for more information.

©2021 Lundbeck. All rights reserved. VYEPTI is a registered trademark of Lundbeck Seattle BioPharmaceuticals, Inc. EPT-B-100669